CD9 correlates with cancer stem cell potentials in human B-acute lymphoblastic leukemia cells

被引:43
|
作者
Nishida, Hiroko [1 ,2 ]
Yamazaki, Hiroto [1 ]
Yamada, Taketo [3 ]
Iwata, Satoshi [1 ]
Dang, Nam H. [4 ]
Inukai, Takeshi [5 ]
Sugita, Kanji [5 ]
Ikeda, Yasuo
Morimoto, Chikao [1 ]
机构
[1] Univ Tokyo, Div Clin Immunol, Adv Clin Res Ctr, Inst Med Sci, Tokyo 1088639, Japan
[2] Keio Univ, Sch Med, Dept Internal Med, Div Hematol, Tokyo, Japan
[3] Keio Univ, Sch Med, Dept Pathol, Tokyo 160, Japan
[4] Nevada Canc Inst, Dept Hematol Malignancies, Las Vegas, NV USA
[5] Univ Yamanashi, Dept Pediat, Sch Med, Yamanashi, Japan
关键词
Cancer stem cells; B-acute lymphoblastic leukemia; CD9; EXPRESSION; POPULATION; CARCINOMA; MARKER; ALPHA;
D O I
10.1016/j.bbrc.2009.02.123
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Cancer stem cell (CSC) theory suggests that only a small subpopulation of cells having stem cell-like potentials can initiate tumor development. While recent data on acute lymphoblastic leukemia (ALL) are conflicting, some studies have demonstrated the existence of such cells following CD34-targeted isolation of primary samples. Although CD34 is a useful marker for the isolation of CSCs in leukemias, the identification of other specific markers besides CD34 has been relatively unsuccessful. To identify new markers, we first performed extensive analysis of surface markers on several B-ALL cell lines. Our data demonstrated that every B-ALL cell line tested did not express CD34 but certain lines contained cell populations with marked heterogeneity in marker expression. Moreover, the CD9(+) cell population possessed stern cell characteristics within the clone, as demonstrated by in vitro and transplantation experiments. These results suggest that CD9 is a useful positive-selection marker for the identification of CSCs in B-ALL. (C) 2009 Elsevier Inc. All rights reserved.
引用
收藏
页码:57 / 62
页数:6
相关论文
共 50 条
  • [1] Regulation of cancer stem cell properties by CD9 in human B-acute lymphoblastic leukemia
    Yamazaki, Hiroto
    Xu, C. Wilson
    Naito, Motohiko
    Nishida, Hiroko
    Okamoto, Toshihiro
    Ghani, Farhana Ishrat
    Iwata, Satoshi
    Inukai, Takeshi
    Sugita, Kanji
    Morimoto, Chikao
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2011, 409 (01) : 14 - 21
  • [2] Evaluation of CD9 as a Candidate Leukemia Stem Cell Marker In Childhood Precursor B Cell Acute Lymphoblastic Leukemia
    Satake, Noriko
    Chang, Astra
    McLaughlin, Bridget
    Bauman, Sara
    Chan, James
    Sarangi, Susmita
    Zhou, Ping
    Kenny, Elaina
    Kraynov, Liliya
    Arnott, Sarah
    McGee, Jeannine
    Nolta, Jan A.
    BLOOD, 2010, 116 (21) : 1329 - 1329
  • [3] AT1412, a Patient-Derived Antibody in Development for the Treatment of CD9 Positive Precursor B-Acute Lymphoblastic Leukemia
    De Jong, Greta
    Levie, Sophie E.
    Schotte, Remko
    Pos, Wouter
    Go, Daniel
    Yasuda, Etsuko
    Cercel, Madalina
    van Hal-van Veen, Susan E.
    Frankin, Esmay
    Szabo, Aniko
    Villaudy, Julien
    van Helden, Pauline M.
    van Eenennaam, Hans
    Spits, Hergen
    Rijneveld, Anita W.
    Hazenberg, Mette D.
    BLOOD, 2019, 134
  • [4] CD38 Is a Functional Partner of CD9 in B-Cell Precursor Acute Lymphoblastic Leukemia
    Chung, Po Yee
    Chan, Kathy Yuen Yee
    Zhang, Chi
    Xu, Yaqun
    Ng, Wing Hei
    Li, Chi Kong
    Leung, Kam Tong
    BLOOD, 2023, 142
  • [5] CD9 shapes glucocorticoid sensitivity in pediatric B-cell precursor acute lymphoblastic leukemia
    Zhang, Chi
    Chan, Kathy Yuen Yee
    Ng, Wing Hei
    Cheung, John Tak Kit
    Sun, Qiwei
    Wang, Han
    Chung, Po Yee
    Cheng, Frankie Wai Tsoi
    Leung, Alex Wing Kwan
    Zhang, Xiao-Bing
    Lee, Po Yi
    Fok, Siu Ping
    Lin, Guanglan
    Poon, Ellen Ngar Yun
    Feng, Jian-Hua
    Tang, Yan-Lai
    Luo, Xue-Qun
    Huang, Li-Bin
    Kang, Wei
    Tang, Patrick Ming Kuen
    Huang, Junbin
    Chen, Chun
    Dong, Junchao
    Mejstrikova, Ester
    Cai, Jiaoyang
    Liu, Yu
    Shen, Shuhong
    Yang, Jun J.
    Yuen, Patrick Man Pan
    Li, Chi Kong
    Leung, Kam Tong
    HAEMATOLOGICA, 2024, 109 (09) : 2833 - 2845
  • [6] CD90 and CD110 correlate with cancer stem cell potentials in human T-acute lymphoblastic leukemia cells
    Yamazaki, Hiroto
    Nishida, Hiroko
    Iwata, Satoshi
    Dang, Nam H.
    Morimoto, Chikao
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2009, 383 (02) : 172 - 177
  • [7] SHEDDING OF CD9 ANTIGEN IN ACUTE LYMPHOBLASTIC-LEUKEMIA
    KOMADA, Y
    SAKURAI, M
    LEUKEMIA & LYMPHOMA, 1994, 12 (5-6) : 365 - &
  • [8] THERAPEUTIC MECHANISMS OF CD9 NEUTRALIZING ANTIBODIES IN PEDIATRIC B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA
    Cheung, John Tak Kit
    Zhang, Chi
    Ng, Wing Hei
    Chan, Kathy Yuen Yee
    Wang, Han
    Li, Chi Kong
    Leung, Kam Tong
    PEDIATRIC BLOOD & CANCER, 2022, 69
  • [9] THE TETRASPANIN CD9 SHAPES GLUCOCORTICOID SENSITIVITY IN PEDIATRIC B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA
    Ng, Wing Hei
    Zhang, Chi
    Cheung, John Tak Kit
    Wang, Han
    Yuen, Kathy
    Chan, Yee
    Li, Chi Kong
    Leung, Kam Tong
    PEDIATRIC BLOOD & CANCER, 2022, 69
  • [10] CD9 expression indicates a poor outcome in acute lymphoblastic leukemia
    Liang, Peiqi
    Miao, Miao
    Liu, Zhuogang
    Wang, Hongtao
    Jiang, Wei
    Ma, Shiyu
    Li, Chuan
    Hu, Rong
    CANCER BIOMARKERS, 2018, 21 (04) : 781 - 786